Intervention Protocol

You have free access to this content

Genetic testing for prevention of severe drug-induced skin rash

  1. Ana Alfirevic1,*,
  2. Munir Pirmohamed1,
  3. Branka Marinovic2,
  4. Andrea L Jorgensen3,
  5. Linda Harcourt-Smith4

Editorial Group: Cochrane Skin Group

Published Online: 19 DEC 2013

DOI: 10.1002/14651858.CD010891


How to Cite

Alfirevic A, Pirmohamed M, Marinovic B, Jorgensen AL, Harcourt-Smith L. Genetic testing for prevention of severe drug-induced skin rash (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD010891. DOI: 10.1002/14651858.CD010891.

Author Information

  1. 1

    Institute of Translational Medicine, University of Liverpool, Department of Molecular and Clinical Pharmacology, Liverpool, UK

  2. 2

    University Hospital Center Zagreb, School of Medicine University of Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia

  3. 3

    University of Liverpool, Centre for Medical Statistics and Health Evaluation, Liverpool, UK

  4. 4

    The University of Nottingham, c/o Cochrane Skin Group, Nottingham, UK

*Ana Alfirevic, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Centre for Personalised Medicine, Block A: Waterhouse Building, 1-5 Brownlow Street, Liverpool, L69 3GE, UK. Ana.Alfirevic@liverpool.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 DEC 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects of prospective pharmacogenetic screening to reduce drug-associated skin reactions in a patient population.